An overview of currently available anti-insulin-like growth factor I receptor antibodies

BioScience Trends

Volumn 1, Issue 3, 2007, Pages 128-133

  Kusada, Yu ^a,b   Fujita Yamaguchi, Yoko ^a,b  

^a TOKAI UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Antibody; Cancer therapy; Epitope specificity; Hormone; Insulin like growth factor I receptor

Indexed keywords

ANTIBODY; SOMATOMEDIN C RECEPTOR;

ANIMAL; BIOLOGICAL MODEL; EPITOPE MAPPING; HUMAN; IMMUNOLOGY; METHODOLOGY; NEOPLASM; REVIEW;

ANIMALS; ANTIBODIES; EPITOPE MAPPING; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; RECEPTOR, IGF TYPE 1;

EID: 53049096108     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-497.
2. Cabilly S, Riggs AD, Pande H, Shively JE, Holmes WE, Rey M, Perry LJ, Wetzel R, Heyneker HL. Generation of antibody activity from immunoglobulin polypeptide chains produced in Escherichia coli. Proc Natl Acad Sci U S A 1984; 81:3273-3277.
3. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigenbinding domains with human constant region domains. Proc Natl Acad Sci U S A 1984; 81:6851-6855.
4. Boulianne GL, Hozumi N, Shulman MJ. Production of functional chimaeric mouse/human antibody. Nature 1984; 312:643-646.
5. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986; 321:522-525.
6. Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol 2005; 23:1105-1116.
7. Lonberg N. Human antibodies from transgenic animals. Nat Biotechnol 2005; 23:1117-1125.
8. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23:1147-1157.
9. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23:1073-1078.
10. Haddad T, Yee D. Targeting the insulin-like growth factor axis as a cancer therapy. Future Oncol 2006; 2:101-110.
11. Ibrahim YH, Yee D. Insulin-like growth factor-I and breast cancer therapy. Clin Cancer Res 2005; 11:944-950.
12. Yee D. Targeting insulin-like growth factor pathways. Br J Cancer 2006; 94:465-468.
13. Miller BS, Yee D. Type I insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Res 2005; 65:10123-10127.
14. Daughaday WH, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 1989; 10:68-91.
15. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, LeRoith D. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A 1999; 96:7324-7329.
16. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995; 16:143-163.
17. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003; 195:127-137.
18. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2007; 28:20-47.
19. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, Le Bon T, Kathuria S, Chen E, Jacobs S, Francke U, Ramachandran J, Fujita-Yamaguchi Y. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 1986; 5:2503-2512.
20. Larsson O, Girnita A, Girnita L. Role of insulin-like growth factor 1 receptor signaling in cancer. Br J Cancer 2005; 92:2097-2101.
21. Pandini G, Mineo R, Frasca F, Roberts CT Jr, Marcelli M, Vigneri R, Belfiore A. Androgens up-regulate the insulinlike growth factor-I receptor in prostate cancer cells. Cancer Res 2005; 65:1849-1857.
22. Pandini G, Vigneri R, Costantino A, Frasca F, Ippolito A, Fujita-Yamaguchi Y, Siddle K, Goldfine ID, Belfiore A. Insulin and insulin-like growth factor-Ι (IGF-Ι) receptor overexpression in breast cancers leads to insulin/IGF-Ι hybrid receptor overexpression: evidence for a second mechanism of IGF-Ι signaling. Clin Cancer Res 1999; 5:1935-1944.
23. Pandini G, Frasca, F, Mineo R, Sciacca L, Vigneri R, Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 2002; 277:39684-39695.
24. Kull FC Jr, Jacobs S, Su YF, Svoboda ME, Van Wyk JJ, Cuatrecasas P. Monoclonal antibodies to receptors for insulin and somatomedin-C. J Biol Chem 1983; 258:6561-6566.
25. Li SL, Kato J, Paz IB, Kasuya J, Fujita-Yamaguchi Y. Two new monoclonal antibodies against the alpha subunit of the human insulin-like growth factor-I receptor. Biochem Biophys Res Commun 1993; 196:92-98.
26. Xiong L, Kasuya J, Li SL, Kato J, Fujita-Yamaguchi Y. Growth-stimulatory monoclonal antibodies against human insulin-like growth factor I receptor. Proc Natl Acad Sci U S A 1992; 89:5356-5360.
27. Keyhanfar M, Forbes, BE, Cosgrove, LJ, Wallace, JC, Booker GW. Production and characterization of monoclonal antibodies against insulin-like growth factor type 1 receptor (IGF-1R). Hybridoma 2006; 25:230-237.
28. Soos MA, Field CE, Lammers R, Ullrich A, Zhang B, Roth RA, Andersen AS, Kjeldsen T, Siddle K. A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity. J Biol Chem 1992; 267:12955-12963.
29. Gustafson TA, Rutter WJ. The cysteine-rich domains of the insulin and insulin-like growth factor I receptors are primary determinants of hormone binding specificity. Evidence from receptor chimeras. J Biol Chem 1990; 265:18663-18667.
30. Mynarcik DC, Williams PF, Schaffer L, Yu GQ, Whittaker J. Identification of common ligand binding determinants of the insulin and insulin-like growth factor 1 receptors. J Biol Chem 1997; 272:18650-18655.
31. Whittaker J, Groth AV, Mynarcik DC, Pluzek L, Gadsbøll VL, Whittaker LJ. Alanine scanning mutagenesis of a type 1 insulin-like growth factor receptor ligand binding site. J Biol Chem 2001; 276:43980-433986.
32. Keyhanfar M, Booker GW, Whittaker J, Wallace JC, Forbes BE. Precise mapping of an IGF-I-binding site on the IGF-1R. Biochem J 2007; 401:269-277.
33. Garrett TP, McKern NM, Lou M, Frenkel MJ, Bentley JD, Lovrecz GO, Elleman TC, Cosgrove LJ, Ward CW. Crystal structure of the first three domains of the type-1 insulin-like growth factor receptor. Nature 1998; 394:395-399.
34. Schumacher R, Soos MA, Schlessinger J, Brandenburg D, Siddle K, Ullrich A. Signaling-competent receptor chimeras allow mapping of major insulin receptor binding domain determinants. J Biol Chem 1993; 268:1087-1094.
35. Kusada Y, Morizono T, Matsumoto-Takasaki A, Sakai K, Sato S, Asanuma H, Takayanagi A, Fujita-Yamaguchi Y. Construction and characterization of single-chain antibodies against human insulin-like growth factor-I receptor from hybridomas producing 1H7 or 3B7 monoclonal antibody. J Biochem (Tokyo) in press.
36. Delafontaine P, Ku L, Ververis JJ, Cohen C, Runge MS, Alexander RW. Epitope mapping of the alpha-chain of the insulin-like growth factor I receptor using antipeptide antibodies. J Mol Cell Cardiol 1994; 26:1659-1673.
37. Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull FC Jr, Allred DC, Osborne CK. Blockade of the type Ι somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 1989; 84:1418-1423.
38. Gansler T, Furlanetto R, Gramling TS, Robinson KA, Blocker N, Buse MG, Sens DA, Garvin AJ. Antibody to type Ι insulinlike growth factor receptor inhibits growth of Wilms' tumor in culture and in athymic mice. Am J Pathol 1989; 135:961-966.
39. Arteaga CL, Osborne CK. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res 1989; 49:6237-6241.
40. Cara JF, Stuart CA, Furlanetto RW. A monoclonal antibody to the type 1 insulin-Like growth factor and insulin receptors stimulates deoxyribonucleic acid synthesis in human and murine fibroblasts. Endocrinology 1988; 123:1341-1347.
41. Morgan DO, Roth RA. Identification of a monoclonal antibody which can distinguish between two distinct species of the type Ι receptor for insulin-like growth factor. Biochem Biophys Res Commun 1986; 138:1341-1347.
42. Hailey J, Maxwell E, Koukouras K, Bishop WR, Pachter JA, Wand Y. Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells. Mol Cancer Ther 2002; 1:1349-1353.
43. Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM, Blättler WA, Chittenden T, Singh R. An anti-insulin-like growth factor Ι receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003; 63:5073-5083.
44. Li SL, Liang SJ, Guo N, Wu AM, Fujita-Yamaguchi Y. Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth. Cancer Immunol Immunother 2000; 49:243-252.
45. Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res 2003; 63:627-635.
46. Ye JJ, Liang SJ, Guo N, Li SL, Wu AM, Giannini S, Sachdev D, Yee D, Brunner N, Ikle D, Fujita-Yamaguchi Y. Combined effects of tamoxifen and a chimeric humanized single chain antibody against the type I IGF receptor on breast tumor growth in vivo. Horm Metab Res 2003; 35:836-842.
47. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS, Moyer JD. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 2005; 11:2063-2073.
48. Burtrum D, Zhu Z, Lu D, et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 2003; 63:8912-8921.
49. Wu JD, Odman A, Higgins LM, Haugk K, Vessella R, Ludwig DL, Plymate, SR. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen independent xenograft human prostate tumors. Clin Cancer Res 2005; 11:3065-3074.
50. Wu JD, Haugk K, Coleman I, Woodke L, Vessella R, Nelson P, Montgomery RB, Ludwig DL, Plymate SR. Combined in vivo effect of A12, a type 1 insulinlike growth factor receptor antibody, and docetaxel against prostate cancer tumors. Clin Cancer Res 2006; 12:6153-6160.
51. Allen GW, Saba C, Armstrong EA, Huang SM, Benavente S, Ludwig DL, Hicklin DJ, Harari PM. Insulin-like growth factor-I receptor signaling blockade combined with radiation. Cancer Res 2007; 67:1155-1162.
52. Wang Y, Hailey J, Williams D, et al. Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol Cancer Ther 2005; 4:1214-1221.
53. Goetsch L, Gonzalez A, Leger O, Beck A, Pauwels PJ, Haeuw JF, Corvaia N. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 2005; 113:316-328.
54. Pandini G, Wurch T, Akla B, Corvaia N, Belfiore A, Goetsch L. Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur J Cancer 2007; 43:1318-1327.
55. Neuenschwander S, Roberts CT Jr, LeRoith D. Growth inhibition of MCF7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. Endocrinology 1995; 136:4298-4303.
56. Hopfner M, Sutter AP, Huether A, Baradari V, Scherubl H. Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer. World J Gastroenterol 2006; 12:5635-5643.
57. Warshamana-Greene GS, Litz J, Buchdunger E, Hofmann F, Garcia-Echeverría C, Krystal GW. The insulin-like growth factor-Ι (IGF-Ι) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-Ι and stem cell factor signaling. Mol Cancer Ther 2004; 3:527-535.
58. Sachdev D, Singh R, Fujita-Yamaguchi Y, Yee D. Downregulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res 2006; 66:2391-2402.
59. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A, Vigneri R. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 1999; 19:3278-3288.
60. Zhang H, Pelzer AM, Kiang DT, Yee D. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res 2007; 67:391-397.